0.5600USD-24.12%Mkt Cap: —P/E: —3d ago
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat live…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)45.08M $
Gross Profit38.19M $
Net Income (TTM)-39.23M $
Revenue/Share0.9010 USD
Last Price0.5600 USD
Fiscal Year End—
MR Quarter—
Employees102
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.68
EPS (TTM)—
EPS (Forward)—
52W Range
0.44103% of range5.000
52W High5.000 USD
52W Low0.4410 USD
Profitability
Gross Margin84.57%
Oper. Margin-86.03%
EBITDA Margin-66.44%
Profit Margin-86.88%
ROE115.85%
ROA-111.03%
Growth
Revenue Growth1.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.01M $
CapEx (TTM)918.00K $
FCF Margin-24.13%
FCF Yield—
Net Debt-11.86M $
Net Debt/EBITDA0.40
Balance Sheet
Debt/Equity-1.02
Current Ratio5.35
Quick Ratio4.72
Book Value/Sh0.2090 USD
Cash/Share0.7520 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float49.50M
Insiders—
Institutions—
Technical
SMA 500.8345 (-32.9%)
SMA 2001.085 (-48.4%)
Beta0.43
S&P 52W Chg18.16%
Avg Vol (30d)2.49K
Avg Vol (10d)610
Technical Indicators
RSI (14)35.9
MACD-0.0972
MACD Signal-0.0867
MACD Hist.-0.0105
BB Upper1.158 USD
BB Middle0.8273 USD
BB Lower0.4966 USD
BB Width79.94%
ATR (14)0.1792 USD
Vol Ratio (20d)0.00x